Core Viewpoint - Pfizer's declining COVID-19 cash flows are expected to result in minimal growth for 2026, with mergers and acquisitions taking time to yield results [1][3]. Financial Performance - Pfizer's stock closed at $25.53, down 3.41%, with a market capitalization of $150 billion [2]. - The company has trimmed its 2025 revenue guidance to $62 billion, down from a previous range of $61 billion to $64 billion, and reaffirmed its adjusted EPS for 2025 at $3.00 to $3.15 [5]. - For 2026, Pfizer anticipates flat growth with revenues projected between $59.5 billion and $62.5 billion, primarily due to declining revenue from COVID-19 drugs and expiring patents [5]. Market Impact - Pfizer's announcement led to a negative impact on its industry peers, with Merck and Johnson & Johnson experiencing declines of 1.99% and 2.27%, respectively, as investors reassessed the earnings potential of large pharmaceutical companies [4]. Strategic Initiatives - The company is implementing cost-cutting measures and reallocating funds towards research and development, including a recent acquisition of a biopharmaceutical company focused on obesity and cardiometabolic diseases [6]. - Pfizer plans to advance obesity drug trials in 2026, although it may take time for these new initiatives to generate significant results [6].

[Music] Welcome back to Squawkbox. A group of nine former CDC directors and acting directors blasting Robert F. Kennedy Jr..'s leadership of the Department of Health and Human Services. In a New York Times oped, the authors criticized Kennedy for weakening programs designed designed to protect Americans from cancer, downplaying vaccines, cancelling investments in medical research, and replacing experts on federal health committees with what they call unqualified individuals. The op-ed follows Trump administ ...

accusing him of endangering every American's health. Tonight, nine former heads of the CDC slamming Health and Human Services Secretary Robert F. Kennedy Jr.. in a blistering New York Times op-ed. In it, blasting Kennedy's firing of CDC director Dr. . Susan Minarz last week that sparked outrage within the agency.Four top leaders resigning in protest. Last week, staffers cheered outside CDC headquarters in support. The former CDC heads writing Minarez refused to quote rubber stamp his dangerous and unfounded ...